Koyama S, Yu H, Dalgarno DC, Shin TB, Zydowsky LD, Schreiber SL. 1H and 15N assignments and secondary structure of the PI3K SH3 domain. FEBS Lett. 1993;324(1):93-8.
Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber SL. Structural basis for the binding of proline-rich peptides to SH3 domains. Cell. 1994;76(5):933-45.
Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369(6483):756-8. doi:10.1038/369756a0
Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell. 1995;82(1):121-30.
Abazeed ME, Adams DJ, Hurov KE, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013;73(20):6289-98. doi:10.1158/0008-5472.CAN-13-1616
Kuruvilla FG, Schreiber SL. The PIK-related kinases intercept conventional signaling pathways. Chem Biol. 1999;6(5):R129-36. doi:10.1016/S1074-5521(99)80070-2
Hardwick JS, Kuruvilla FG, Tong JK, Shamji AF, Schreiber SL. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc Natl Acad Sci U S A. 1999;96(26):14866-70.
Shamji AF, Nghiem P, Schreiber SL. Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell. 2003;12(2):271-80.
Butcher RA, Bhullar BS, Perlstein EO, Marsischky G, LaBaer J, Schreiber SL. Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway. Nat Chem Biol. 2006;2(2):103-9. doi:10.1038/nchembio762
Yang J, Shamji A, Matchacheep S, Schreiber SL. Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem Biol. 2007;14(4):371-7. doi:10.1016/j.chembiol.2007.02.004